Replimune Group, Inc. (REPL) stock analysis

In our weekly check, Replimune Group, Inc. is graded F (A to F). Of 19 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 11.

Sector: Healthcare · Biotechnology

Strengths

Warning signs

Next earnings report: 2026-11-05

Similar companies

JANX · TRAX · BCAX · VOR · TYRA

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-10

Open the full analysis